About us

About us2018-11-02T09:17:37+00:00

A company founded on science

Atrogi was founded in 2013 by professor Tore Bengtsson with support from private investors. Professor Bengtsson has been conducting ground-breaking research on adrenergic signaling at Stockholm University for over 15 years and discovered how to selectively stimulate blood glucose uptake in skeletal muscle. This evidence is used to develop a treatment of T2D that produces minimal side effects.

  • Data Driven – Compounds are synthesized and analyzed in an iterative fashion

  • Results Orientated – The data is used to produce compounds aimed at the treatment of T2D

  • Research Led – Extensive experience from research and development from academia and industry

  • Patentable – Atrogi has a thought-through intellectual property strategy and a robust patent portfolio

Unprecedented scientific expertise from academia and broad drug development competence from the pharmaceutical industry is the perfect set-up for reaching the goal of developing a treatment of T2D.

Focus on marketable results

Atrogi has within its realm, leading experts who know what it takes to bring a compound through clinical studies and into the market. Our focus is to create value by developing a drug that will transform todays T2D treatment.

The process of bringing a compound from research and development and through to clinic stages and into the market is always a challenge. With a combination of solid experience from clinical and business development Atrogi is perfectly poised to achieve the goal of successfully bringing a unique treatment of T2D to the market.

Meet Our Team

Alexandra Ekman Ryding
CEO
  • PhD Medical Epidemiology
  • Experience in venture capital and corporate broking
  • Experience in health economics and outcomes research
  • Member of the board of directors of several organisations and companies
Benjamin Pelcman
COO
  • PhD Organic Chemistry
  • 25 years industrial experience in drug development
  • Experience from several pharma collaborations
  • 10 years experience in scientific research
  • 50+ patent applications
  • 20+ scientific publications
Tore Bengtsson
Founder & CSO
  • Professor in Physiology at Stockholm University
  • 25 years experience in pharmacology and physiology
  • 50+ scientific publications
  • 10+ patent applications
  • Entrepreneur and founder of several companies
Nodi Dehvari
Head of Biology
  • PhD Neuroscience
  • 13 years experience in scientific research
  • 16 scientific publications
  • Unique knowledge of MOA
  • Experienced teambuilder

Meet Our Board of Directors

Tore Bengtsson
Founding Board member – 2013

Education

  • Professor in Physiology at Stockholm University

Experience

  • 25 years experience in pharmacology and physiology
  • 50+ scientific publications
  • 10+ patent applications

Other assignments:

  • Co-founder of Symcel AB, Glucox AB, Sigrid Therapeutics AB
Maarten De Château
Head of the Board since 2017

Education

  • MD and PhD in Cell and Molecular Biology, Lund University

Experience

  • Medical Director, Swedish Orphan Biovitrum
  • Medical Advisor, Sanofi
  • Financial analyst, Aragon Securities, Swedbank Markets
  • CEO and Founder of Cormorant Pharmaceuticals

Other assignments:

  • CEO of Sixthera AB
  • Board member of Oxthera AB, Cavis Technologies AB, AddBio AB, SVP Medical Strategy and Innovation, Camurus AB
Åsa Inde
Board member since 2015

Education

  • BSc in Physical Therapy
  • Degree from Business Education Institute (FEI)

Experience

  • 25 years of business development
  • Founder of Frösundagruppen and Team Olivia

Other assignments

  • Board member of Creperie & Logi AB, Gotlandsbyggen AB, Hemsehem AB, Abisko AS, Markethill Inc and Comai AB
Giovanni Fili
Founding Board member – 2013

Bio coming soon

Robert Taflin
Founding Board member – 2013

Bio coming soon

Roger Berlin
Board member since 2017

Education

  • M.D., Weil Cornell Medical College
  • Advance Management Program, Harvard Business School

Experience

  • Founder & Principal – 1.618 Consulting LLC
  • Chief Medical Advisor – Banner Health Science
  • Board of Directors – rTerra
  • CEO – Arno Therapeutic
  • President Global R&D – Wyeth Consumer Healthcare
  • Executive Director of International Regulatory, Merck
  • Executive Director Clinical Research – Merck Research Laboratories
  • Gastroenterologist in Clinical Practice
  • Resident & Research Fellow in Gastroenterology – Stanford U Hospital

Other assignments

  • Board member – Sigrid Therapeutics AB,
  • Scientific and Regulatory Advisory Board – 3D Communications
Carl-Johan Spak
Board member since 2017

Education

  • PhD in Dentistry Karolinska Institutet

Experience

  • Executive Vice President, Global Technologies, Recipharm AB
  • Director Nordic Region, Country Manager Sweden, Meda AB, CEO Recip AB and Recip Läkemedel AB

Other assignments

  • Board member of Empros Pharma AB, Symcel Sweden AB, Xspray Pharma AB, Pharmanest AB, Prokarium Ltd, Synthonics Inc, KAHR Medical Ltd, Cobra Biologics Holding AB

“My career and passion has been in pharmaceuticals. Coming here to Atrogi has been one of my most exciting opportunities yet. The prospect of developing a treatment that would benefit so many patients is extremely exciting. I can’t wait to see the first Atrogi solution on the market!”

Benjamin Pelcman, CEO

Discover The Future

We are a multi-disciplinary team committed to focused and efficient drug development

Contact Us